Health related quality of life (HRQoL) in childhood survivors of refractory GvHD treated with mesenchymal stromal cell infusions - a multi-center study

• Conditions: Beenmergtransplantatie; bone marrow transplantations; malignant diseases; 10024324; 10021460

• Registration Number: NL-OMON32001
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

Patients who have undergone treatment with MSC*s for steroid refractory acute GvHD and are at least one month post infusion
Anticipated life expectancy > 1 month.
Signed informed consent by the patient and/or parent(s) or legal guardian(s).
Aged between 2-18 years

Exclusion Criteria

Expected life expectancy < 1 month

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Health related quality of life, measured by the PEDS QL and clinical status<br /><br>assessment.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable.</p><br>